Helsinn Healthcare SA

vorige Seite Seite 1 von 3 nächste Seite

Helsinn Therapeutics (U.S.), Inc. Strengthens its Board of Directors

Helsinn Group, the Company focused on building quality cancer care, announced today the appointment of Dr. Philip S. Schein, to the Board of Directors of its U.S.

25.06.2014 14:36

Helsinn promotes the use of mobile technology in cancer supportive care through mobile health

The pharmaceutical group in Ticino, global leader in cancer supportive care, supports the International Conference on mobile technology dedicated to improve the quality of life of people with cancer in …

01.04.2014 13:14

Helsinn Named as One of the Best Places to Work in New Jersey by NJBIZ

Helsinn Group, the company focused on building quality cancer care, is pleased to announce today that its U.S.

13.03.2014 14:01

Helsinn announces European Medicines Agency acceptance of regulatory submission for netupitant-palonosetron fixed dose combination (NEPA)

The Swiss pharmaceutical Helsinn Group announced today that on January 22nd the European Medicines Agency (EMA) determined netupitant-palonosetron fixed dose combination (NEPA) Marketing Authorisation …

29.01.2014 12:02

Helsinn Group and Angelini ink an agreement for license rights to phase-III ghrelin receptor agonist Anamorelin in Central & Eastern Europe

Swiss Pharma Group Helsinn grants exclusive distribution and licensing rights to Angelini, through its subsidiary company CSC Pharmaceuticals, for the commercialization in Austria, Bulgaria, Czech Republic, …

15.01.2014 12:11

Swiss-based Helsinn Group and Mundipharma sign for rights to Phase III Netupitant-Palonosetron fixed dose combination for China

The two companies sign a distribution and license agreement for an investigational therapy for the prevention of chemotherapy-induced nausea and vomiting covering China, Hong Kong and Macao

19.12.2013 08:02

Helsinn and Italfarmaco reinforce their alliance through the grant of rights to phase-III ghrelin receptor agonist Anamorelin in Italy

Helsinn Group is pleased to announce that exclusive distribution and licensing rights to its innovative ghrelin receptor agonist, anamorelin, in Italy, San Marino and Vatican City have been granted to its …

18.12.2013 12:29
vorige Seite nächste Seite